Dec 12, 2022 / 03:30PM GMT
Operator
Hello, ladies and gentlemen. I am pleased to welcome you to Autolus Therapeutics ASH 2022 Investor Conference Call. As a reminder, this conference call is being recorded.
I would now like to turn the conference call over to your host, Olivia Manser, Director, Investor Relations. Please go ahead.
Olivia Manser - Autolus Therapeutics plc - Director of IR
Thanks, Justin. Hi, everyone, good afternoon or good morning, and thanks for joining us and taking part in today's call, in which we'll be covering the data we're presenting at the ASH conference. So this is Olivia. On the call, as usual, are Dr. Christian Itin, our Chief Executive Officer; and Dr. Lucinda Crabtree, our Chief Financial Officer.
So before we begin, as always, just to remind you that during today's call, our discussion will contain forward-looking statements and those are on Slide 2. So please make sure you're familiar with the disclaimer slide.
And with that, I'll hand over to Christian to summarize the data. And afterwards, we will welcome your questions. So over to
Autolus Therapeutics PLC to Summarize the ASH Data Transcript
Dec 12, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers